We are live on ! Find out more
TFFP

TFF Pharmaceuticals, Inc. Common Stock

Delisted

TFFP was delisted on the 12th of December, 2024.

63 hedge funds and large institutions have $96.1M invested in TFF Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

73% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 11

56% more call options, than puts

Call options by funds: $3.3M | Put options by funds: $2.11M

34% more funds holding

Funds holding: 4763 (+16)

4% more capital invested

Capital invested by funds: $92.8M → $96.1M (+$3.26M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
63
Holders Change
+16
Holders Change %
+34.04%
% of All Funds
1.11%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
24
Increased
19
Reduced
11
Closed
8
Calls
$3.3M
Puts
$2.11M
Net Calls
+$1.19M
Net Calls Change
+$2.31M
Name Holding Trade Value Shares
Change
Change in
Stake
CA
1
Corriente Advisors
Texas
$21.2M +$3.51M +8,627 +16%
Vanguard Group
2
Vanguard Group
Pennsylvania
$9.46M +$1.14M +2,805 +11%
DS
3
DRW Securities
Illinois
$6.97M +$8.35M +20,536 New
NCM
4
Nantahala Capital Management
Connecticut
$5.19M -$22.5M -55,237 -78%
GS
5
Gagnon Securities
New York
$5.13M +$2.36M +5,804 +62%
Hudson Bay Capital Management
6
Hudson Bay Capital Management
Connecticut
$4.82M -$2.36M -5,800 -29%
BlackRock
7
BlackRock
New York
$3.87M +$82.5K +203 +2%
ACM
8
Altium Capital Management
New York
$3.66M +$4.39M +10,788 New
Millennium Management
9
Millennium Management
New York
$3.25M +$2.24M +5,498 +134%
GPCM
10
Granite Point Capital Management
Massachusetts
$2.85M +$3.42M +8,400 New
IAM
11
Iridian Asset Management
Connecticut
$2.77M +$3.32M +8,154 New
ACA
12
Apis Capital Advisors
New York
$2.48M +$2.97M +7,300 New
GA
13
Gagnon Advisors
New York
$2.4M
CC
14
Carlson Capital
Texas
$2.31M +$2.77M +6,800 New
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$2.25M +$947K +2,330 +54%
Janney Montgomery Scott
16
Janney Montgomery Scott
Pennsylvania
$1.69M +$1.16M +2,843 +133%
PM
17
Precept Management
Texas
$1.46M -$695K -1,708 -28%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.45M +$184K +453 +12%
Citadel Advisors
19
Citadel Advisors
Florida
$1.27M +$947K +2,328 +165%
SPC
20
Sigma Planning Corp
Michigan
$921K -$309K -760 -22%
Renaissance Technologies
21
Renaissance Technologies
New York
$878K +$483K +1,188 +85%
PAWC
22
P.A.W. Capital
Connecticut
$864K +$1.04M +2,548 New
HF
23
HRT Financial
New York
$773K +$604K +1,485 +187%
Marshall Wace
24
Marshall Wace
United Kingdom
$773K +$927K +2,279 New
ECM
25
ExodusPoint Capital Management
New York
$685K +$27.2K +67 +3%

TFFP Hedge Fund Activity: Q1 2021 in Review

63 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in TFF Pharmaceuticals, Inc. Common Stock (TFFP) for Q1 2021, worth a combined $96.1M — up 3.5% from $92.8M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new TFFP positions and 8 closed out — a net gain of 16 holders — while 19 added to existing stakes and 11 trimmed.

The largest buyer was DRW Securities, opening a new position worth an estimated $8.35M. The largest seller was Nantahala Capital Management, cutting an estimated $22.5M.

  • 63 institutional investors held TFF Pharmaceuticals, Inc. Common Stock (TFFP) as of Q1 2021, up from 47 in Q4 2020.
  • Funds reported $96.1M of TFF Pharmaceuticals, Inc. Common Stock stock for Q1 2021, up 3.5% quarter-over-quarter.
  • 24 funds opened new TFF Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of +16 holders.
  • The largest TFF Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was DRW Securities, an estimated $8.35M added.
  • The largest TFF Pharmaceuticals, Inc. Common Stock seller in Q1 2021 was Nantahala Capital Management, an estimated $22.5M sold.

Based on aggregated 13F filings for Q1 2021.